MedPath

Monitoring of Progesterone Administered in Infertile Patients During a Cycle of Frozen Embryo Transfer.

Not Applicable
Recruiting
Conditions
IVF
Interventions
Other: Questionnaire
Registration Number
NCT05109676
Lead Sponsor
University Hospital, Toulouse
Brief Summary

During an In Vitro Fertilization (IVF) attempt, several embryos are obtained but not all of them can be transferred to the uterus in the same cycle due to the risk of multiple pregnancies. Thus, it is very common for these couples to benefit from cryopreservation. Patients scheduled for frozen embryo transfer (TEC) receive estrogen and progesterone replacement therapy to prepare the endometrium for implantation. Data from the literature recently showed that low progesterone on the day of embryo transfer was responsible for a significantly higher rate of implantation failure and miscarriage.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Adult patient undergoing a frozen embryo transfer in an artificial cycle at the AMP center of the Toulouse University Hospital.
  • Affiliation to a social security scheme or equivalent
  • Patient fulfilling the conditions for access to the AMP according to French bioethics law
  • Patient having given her consent (oral or written) after clear and fair information
Exclusion Criteria
  • Patient who received intramuscular administration of progesterone during the endometrial preparation phase.
  • Patient with comprehension difficulties.
  • Protected adult patient (safeguard of justice, guardianship or curatorship)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Patients having embryo transfertQuestionnairePatients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 µg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.
Primary Outcome Measures
NameTimeMethod
Average plasma progesterone concentration.Day of embryo transfer.

Dosage of apparent clearance (CL/F)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Toulouse

🇫🇷

Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath